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Abstract
Objectives:
To evaluate levetiracetam (LEV) tolerability in
patients with epilepsy and liver disease.
Methods:
Fourteen patients with epilepsy and concomitant
liver disease were treated with LEV in an open
prospective investigation mimicking the daily
clinical practice. All patients were stabilized (ie,
for at least 1 year) on traditional antiepileptic
drugs with complete or partial control of seizures.
In the 6-month pre-LEV baseline period, seizure
frequency ranged from 3 to 300. Levetiracetam
was added on to the basal treatment at a starting
daily dose of 250 mg, and the dose was adjusted
according to the tolerability and the therapeutic
response. Four patients discontinued the drug
within the first 3 months because of intolerable
side effects. The remaining 10 continued LEV
treatment, and the present follow-up is 12 to 38
months.
Results:
In the last 6 months of observation, none of the
patients showed worsening of liver function on
the basis of blood chemistry, and in 4 patients, a
complete normalization or a trend toward physio-
logical values of transaminase and/or +-glutamyl-
transferase activity was observed. A greater than
50% reduction in seizure frequency occurred in all
uncontrolled patients, 2 of whom achieved seizure
freedom during LEV treatment.
Conclusions:
Based on these observations, LEV seems to be an
attractive therapeutic option in epileptic patients
with chronic liver diseases.
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Antiepileptic therapy in patients withepilepsy and concomitant liver diseases
may raise some concern because most anti-
epileptic drugs (AEDs) undergo hepatic
metabolism, and their biotransformation
may be impaired with possible onset of
adverse effects.1 Additionally, AEDs may
cause liver toxicity and worsen an already
vulnerable liver function.1 Treatment of
these patients, therefore, requires the double
goal of achieving satisfactory seizure control
without affecting the hepatic condition.
Among the recently introduced AEDs,
levetiracetam (LEV) exhibits a favorable
tolerability profile and lacks significant hep-
atic metabolism.2,3 On theoretical grounds,
therefore, this drug is a good candidate for
the treatment of patients with epilepsy and
concomitant liver diseases. To the best of
our knowledge, only very few reports in the
literature describe long-term LEV use in
epileptic patients with hepatic dysfunc-
tion.4,5 Therefore, we deemed of interest to
report our observations with the use of LEV
in a series of 14 patients of this kind.
MATERIALS AND METHODS
The study, a prospective open study
mimicking the daily clinical practice, was
approved by the local ethics committee, and
informed consent was obtained by each
patient before entry. Patients with epilepsy
and concomitant chronic liver diseases were
included if they were stabilized on AED
therapy (ie, no change in drug and drug
dose for at least 12 months) and judged
compliant on the basis of an accurate
anamnesis. Therapy was kept constant for
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the first 6 months of observation (baseline).
Seizure frequency was recorded in an ad hoc
calendar. Patients were investigated if they
were either completely or partiallyAQ5 con-
trolled by therapy. Levetiracetam was then
given as an add-on therapy at a starting
dosage of 250 mg/d. Upward titration was
performed, adding 250 mg every 2 weeks.
Dose was adjusted on clinical grounds by
evaluating both the tolerability and seizure
response to the treatment. Once the optimal
LEV dose was achieved, basal AEDs were
slowly and sequentially reduced, achieving
complete discontinuation in those patients
in which no seizure deterioration was
observed. Seizure deterioration was consid-
ered an increase in seizure frequency of at
least 50% in the last 6 months of follow-up as
compared with the baseline period. Seizure
frequency, blood chemistry including liver
function assessmentAQ6 , and serum LEV concen-
trations were evaluated every 2 months in
the titration period and successively every 4
to 6 months.
Levetiracetam was assayed in serum by
high-performance liquid chromatography.6
In accordance with this procedure, whole
blood was separated within 30 minutes after
patient sampling so as to minimize in situ
LEV metabolism that could result in spuri-
ously low concentrations and substantial
intrapatient variability.6 Blood samples were
collected in fasting conditions. Intradaily and
interdaily CVAQ7 were less than 10%.
RESULTS
Fourteen patients with the previously
described characteristics were investigated.
Details of these patients are given inT1 Table 1.
None of these patients presented with renal
impairment.
At baseline, 2 patients were seizure-
free, and the remaining 12 patients showed a
seizure frequency ranging from 3 to 300
seizures in the 6-month baseline period
(Table 1). After LEV was started, 4 patients
(patients 1Y4) discontinued the drug within
the first 3 months because of intolerable
adverse effects, consisting of confusion,
drowsiness, and headache; 2 of them
(patients 2 and 4) showed also worsening
of seizures. Transient headache was reported
by 2 patients (patients 9 and 10) who,
however, continued LEV treatment. At the
present follow-up (ie, 12Y38 months), 10
patients are stabilized on LEV treatment
(Table 1). In particular, in 5 of these patients
(patients 5, 6, 11, 13, and 14), AED treat-
ment used at study entry was completely
withdrawn, and LEV treatment was contin-
ued as monotherapy. The 2 patients who
were seizure-free at baseline (patients 13 and
14) continued to have a complete seizure
control. All the remaining 8 patients
(patients 5 to 12) were responders to LEV
showing a greater than 50% reduction in
seizure frequency, especially generalized
tonic-clonic seizures. In particular, 2
(patients 6 and 11) of these 8 patients
achieved seizure freedom during LEV treat-
ment. None of the patients showed changes
in blood parameters indicating liver function
deterioration. In 4 patients (patients 6, 10,
11, and 14), transaminase and/or +-glutamyl-
transferase activity reverted to reference
values or showed a significant reduction; in
patients 6, 10, and 14, this result might be
due to withdrawal/reduction of coexisting
enzyme inducing AEDs.
Plasma levels of LEV were within 16 to
32 mg/L. Unlike conventional AEDs, a ther-
apeutic range has not been demonstrated for
the new AEDs, including LEV. The values
detected in our group, however, are similar
to those found in other investigations7 and
indicate that all our patients adhered to the
treatment as prescribed.
DISCUSSION
The observations deriving from the
present investigation are in line with other
literature reports indicating a safe profile of
LEV in patients with liver dysfunction. Apart
from the good tolerability and efficacy of the
drug described in liver transplant patients,4,5
in fact, the pharmacokinetics of LEV in
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patients with mild-to-severe liver cirrhosis
have been investigated in detail.8 This study
has found that no dose adjustment is neces-
sary in patients with mild-to-moderate liver
impairment, but patients with severe cirrho-
sis should initially receive only half of the
commonly recommended dose.8 In our
patients, conventional AEDs were used at
low-to-moderate doses to minimize hepatic
overload and possible worsening of an
already vulnerable liver function. Thus, the
difficulty in achieving the optimal dose
might be the cause of failure, at least in part
and in some patients, in obtaining a com-
plete seizure control with traditional AEDs.
Conversely, reduction or normalization
of transaminase and/or +-glutamyltransferase
activity was observed in 4 patients in which
concomitant AED therapy was withdrawn or
relevantly reduced. Overall, 9 of 14 patients
received beneficial effects from substitution
of conventional AEDs with LEV, concerning
seizure control, liver function improvement,
or both. In conclusion, although the present
investigation has the limitation of a low
number of patients and is an open uncon-
trolled study, it reinforces the few existing
observations in the literature indicating that
LEV is an attractive therapeutic option AQ5in
patients with epilepsy and concomitant liver
diseases. Further studies carried out in a
large cohort of patients and in controlled
conditions are justified to verify whether LEV
can be considered a first-choice drug in this
kind of patients.
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